Tejaswini Kulkarni

This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.

#CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD. Read more in CHEST Daily News: hubs.la/Q02VyD6P0

Our @AnnalsATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in @PFFORG registry is now in press; underscores the importance of addressing mental health. #curePF @ahajaricase @UABPulmonary

@KaminskiMed 🙏🏼

Great talk at #ICLAF2024 by Prof Kulkarni on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure - hope for success 👏🏼👏🏼👏🏼@tkulkarn1 👏🏼👏🏼🙏🏼

@KaminskiMed Fantastic talk and tribute to Andy Tager! #ICLAF2024 #curePF

Getting ready for the Andy Tager Honorary Lecture at #ICLAF2024 with old-time great friends and super #CurePF4All #LungAging reserchers Profs Mora and Rojas, and with the help of the amazing Thanis!

Lessons learnt, cautious optimism and moving forward in clinical trials in ILD - #ICLAF2024

Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF

#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF

Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by @tkulkarn1 and Dr. Danoff. Should our primary emphasis be on enhancing QoL? Active involvement of patients in decision-making processes is key! #CHEST2024 #CHESTTrainees

Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography" Register here: thoracic.zoom.us/meeting/regist…

Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!! #CureIPF boehringer-ingelheim.com/us/topline-res…

To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over the last year #CurePF This paper highlights the innovative REMAP-ILD concept for drug development in fibrotic ILDs @leticiakawano @IPFdoc thorax.bmj.com/content/79/8/7…

@IQuEStHouston @BhavikaKaulMD Congratulations @BhavikaKaulMD

✶Award Announcement!✶ @BhavikaKaulMD, IQuESt Investigator and VA Researcher, has been selected as an inaugural Oscar Auerbach Visiting Scholar with the War Related Illness and Injury Center for her proposal “Novel Radiomics Methods for Phenotypic Assessment of Post-Deployment Lung Disease.” The program is intended to support highly accomplished VA investigators who are pursuing questions pertaining to long-term health outcomes among Veterans with military environmental exposures with a multi-year research award. The program is named in honor of Dr. Oscar Auerbach, a physician scientist who conducted seminal work on the relationship between tobacco smoke and lung cancer, which was cited in the 1964 U.S. Surgeon General Report. Through this award, Dr. Kaul will evaluate the epidemiology of interstitial lung disease among post-deployment Veterans. Please join us in congratulating Dr. Kaul on receiving this prestigious award!

In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF @cnewto

Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing @journal_CHEST journal.chestnet.org/article/S0012-…

@drdayjee @UChicagoMed @UChicagoPCCM @UChicago @Y_Gilad @HGEN_UChicago @UCM_HDS @WF_Parker @michaelwd @FutureDocs @UChiPritzker Fantastic- congratulations 😀

It finally happened… (Re) introducing Dr. Deji Adegunsoye! • Ph.D. Genetics Genomics & Systems Biology🧬 • MSc. Public Health Sciences🏥 • Pulmonologist🫁 • Intensivist🩺 So grateful to all who helped on this journey. This one is for you. We did it!🎉 #PhDone #YesYouCan

A great discussion on the methodology of these upcoming guidelines and key take away points on management of patients with SARD-ILD - #curePF #CHEST_ILDTx @accpchest @ATSCPAssembly @PFFORG

Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that: • Progression of ILD is progression irrespective of time since diagnosis •“despite usual management” should be included in PPF definition Important for future PPF guidelines. #ATS2024

@KaminskiMed @IPFdoc @KerriBerriKerri @TobyMMaher @drdayjee @ahajaricase @dantinozerkis @DoctorSwig @leticiakawano @ericafarrandMD Not enough but more to follow up on this topic!

I wasn’t clear on that. Was there a discussion of Acute Exacerbations of IPF discussed at #ATS2024, the urgent need for treatment trials? @IPFdoc @KerriBerriKerri @TobyMMaher @drdayjee @ahajaricase @tkulkarn1 @dantinozerkis @DoctorSwig @leticiakawano @ericafarrandMD, others?